Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation (CTX)
This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Elizabeth Shane, Columbia University
First received: February 27, 2006
Last updated: February 11, 2013
Last verified: February 2013
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study is ongoing, but not recruiting participants.|
|Estimated Study Completion Date:||January 2014|
|Primary Completion Date:||April 2010 (Final data collection date for primary outcome measure)|
Shane E, Cohen A, Stein EM, McMahon DJ, Zhang C, Young P, Pandit K, Staron RB, Verna EC, Brown R, Restaino S, Mancini D. Zoledronic acid versus alendronate for the prevention of bone loss after heart or liver transplantation. J Clin Endocrinol Metab. 2012 Dec;97(12):4481-90. doi: 10.1210/jc.2012-2804. Epub 2012 Sep 28.